Why You Have Allergies in the Fall

September 14, 2026

Fall brings Big Orange football to East Tennessee, but it can also bring sneezing, congestion, itchy eyes, and fatigue. If your allergies return as summer winds down, ragweed may be a major reason. For some people, the same pollen allergy also helps explain why a bite of melon or banana makes their mouth itch.

 

WHY FALL IS ALLERGY SEASON


Ragweed releases highly allergenic, windborne pollen in late summer and fall. When someone with ragweed allergy breathes it in, their immune system recognizes pollen proteins as a threat and releases chemicals, including histamine, that cause allergy symptoms.


The season often begins in August and continues into autumn, usually ending with a killing frost. Peak timing varies with location and weather, and warmer regions can have a longer season. Ragweed is a leading fall pollen trigger, although other weeds and outdoor mold can contribute too.

 

WHAT RAGWEED ALLERGY FEELS LIKE


Common symptoms include repeated sneezing, a runny or stuffy nose, postnasal drainage, and itching of the nose, throat, or eyes. Eyes may also look red and water frequently. Some patient may even feel excessive fatique.


Ragweed can also aggravate asthma, causing coughing, wheezing, or chest tightness. If fall brings more asthma symptoms or increased use of your rescue inhaler, your treatment plan deserves a review. Your symptom history, together with targeted skin testing for allergen-specific IgE when appropriate, can help identify the cause.

 

WHY MELON OR BANANA CAN MAKE YOUR MOUTH ITCH


Some proteins in raw foods resemble proteins in pollen. In certain people with ragweed allergy, the immune system reacts to these similar food proteins as well. This is called “pollen-food allergy syndrome,” also known as “oral allergy syndrome.”


The classic ragweed-associated foods include:


- Melons: watermelon, cantaloupe, and honeydew

- Banana

- Cucumber

- Zucchini


Symptoms often begin within minutes including itching or tingling of the lips, mouth, or palate, sometimes with mild localized swelling. GI symptoms such as heartburn, abdominal pain, diarrhea, and constipation can also develop in some patients. Food symptoms may become more noticeable during pollen season, but they can happen year-round. However, having ragweed allergy does not mean you will react to these foods.

 

DO YOU NEED TO STOP EATING THESE FOODS


Keep eating foods you tolerate. A cross-reactivity list is not a list of foods everyone with ragweed allergy must avoid.


If a raw food repeatedly causes symptoms, stop eating that form and discuss it with your clinician. Cooking often breaks down the proteins responsible for pollen-food allergy syndrome, so cooked forms may be tolerated. Peeling and removing seeds sometimes helps but does not reliably prevent a reaction.


Reactions to cooked foods, worsening symptoms, or symptoms beyond the mouth need further evaluation. Do not assume cooking makes a food safe after a serious reaction. Your clinician can help determine what to avoid and whether you need an epinephrine autoinjector.

 

WHEN A FOOD REACTION NEEDS URGENT CARE


Most pollen-food reactions stay mild and localized, but serious reactions can occur. Trouble breathing or swallowing, voice changes, faintness, or rapidly progressing throat or tongue swelling are emergency signs. Use epinephrine immediately if available and call 911. Antihistamines do not replace epinephrine for anaphylaxis.


Mild lip swelling is different from swelling that affects the airway, but any progression needs prompt attention. Widespread hives or repeated vomiting after eating also require urgent assessment, especially when symptoms involve more than one part of the body.

 

HOW TO GET AHEAD OF FALL ALLERGIES


Check local pollen counts, keep home and car windows closed on high-pollen days, and shower and change clothes after prolonged outdoor exposure.


Antihistamines can relieve itching and sneezing. For persistent nasal symptoms, especially congestion, a daily corticosteroid nasal spray is often the most effective single treatment. Some patients benefit from a nasal antihistamine or a combination spray. Starting an appropriate regimen before your usual season can improve control.


Consider allergen immunotherapy (aka allergy shots) to can change your immune reactions to allergens over time and diminish your underlying allergic disease. Immunotherapy also treats seasonal respiratory allergy and reduces pollen-food reactions.



At Pienkowski MD, we help patients understand their allergy triggers and develop a treatment plan that fits their symptoms. Explore pienkowskimd.com for clinic information in Knoxville, Greeneville, Johnson City, Kingsport, and Bristol. Go Vols!

By admin November 17, 2021
Anaphylaxis Risk Analysis via Skin Testing with Covid-19 Vaccines Vaccination has been found to be effective in reducing the risks of infection of severe acute respiratory syndrome coronavirus and severe coronavirus disease 2019 (COVID-19) outcomes. In the United States, Pfizer-BioNTech and Moderna COVID-19 vaccines (aka the messenger RNA [mRNA] vaccines) have been used safely for these purposes. 1 , 2 PATIENT HISTORY OF ANAPHYLAXIS First post-market reports on the use of these vaccines describe 4.7 cases of anaphylaxis per million doses of Pfizer vaccine 3 and 2.5 cases per million Moderna doses given. 4 These early reports also describe 43.8 cases of non-anaphylactic allergic reactions per million Pfizer doses given. Among individuals who experienced anaphylaxis to the Pfizer vaccine, 81% had a documented history of allergies triggered by drugs, vaccines, medical products, foods or insect stings, and 33% of these individuals experienced anaphylaxis in the past. Similarly, 90% of individuals with a history of anaphylaxis to the Moderna vaccine had a documented history of allergic reactions, and 50% of these individuals experienced anaphylaxis in the past. POLYETHYLENE GLYCOL IN mRNA VACCINES The presumed causes of allergic reactions are the different polyethylene glycols (PEGs) in the mRNA vaccines. Although PEG allergy is rare, PEG has been found to cause anaphylaxis. 5 Moreover, skin testing of PEGs of differing molecular weights has been found to be effective in confirming anaphylaxis to PEGs in patients with a documented history of anaphylaxis to PEG. 6 Nevertheless, in a cohort of 8 individuals with allergic reactions to the first dosage of an mRNA vaccine, PEG skin testing result was found to be negative. 7 VACCINE PARAMETERS The 2012 vaccine practice parameters published by the American Academy of Allergy, Asthma, and Immunology (AAAAI), recommend that individuals with suspected anaphylaxis to a particular vaccine receive skin testing with that vaccine to evaluate their risk of anaphylaxis. 8 Because the mRNA vaccines contain components other than PEG that may cause allergic reactions, the AAAAI recommendations for evaluating risk of anaphylaxis to vaccines are appropriate for the mRNA vaccines as well. In fact, Greenhawt et. al. 9 recently suggested using the 2012 parameters for patients with a previously documented allergy to one of the mRNA vaccines. 9 Many of our patients who have experienced anaphylaxis express hesitancy toward receiving vaccines, owing to fears of anaphylaxis, and continue to delay their COVID-19 vaccination. To meet this demand, we offered skin testing with mRNA vaccines for our patients who requested evaluation of their risk of anaphylaxis. INITIAL TESTING In this communication, we will describe our first 30 patients (female, n = 27; male, n = 3) who had skin testing with the mRNA vaccines. The patients were either self-referred or referred to us by other physicians. All patients had a self-reported history of anaphylaxis to a variety of substances, including foods, venoms, drugs, environmental, flu vaccine, unknown sources or the first dosage of a COVID-19 mRNA vaccine. The risks and benefits of skin testing were discussed with the patients, and consent forms were accordingly signed. The patients were probed for self-reported reactions to PEG-containing products (ie, toothpaste and colonoscopy preparation). Ages of the patients ranged from 27 to 80 years. Of the patients, 2 had a history of COVID-19 confirmed by polymerase chain reaction testing. Disclosures: The authors have no conflicts of interest to report. Funding: The authors have no funding sources to report. https://doi.org/10.1016/j.anai.2021.09.021 ABOUT THE TEST Skin testing occurred from January 22, 2021, to March 25, 2021. Remnants of the mRNA vaccines were collected on the morning of testing from the Johnson City Medical Center in coordination with the Tennessee Department of Health and used for skin testing within 6 hours from opening of the vials. The patients were advised to refrain from using antihistamines and oral glucocorticoids starting 3 days before the testing. Skin testing was performed on the ventral forearms of the patients using the protocol recommended by the AAAI with modifications to increase safety. Testing began with stan- dard histamine and normal saline applied by prick technique and by intradermal injection of 0.05 mL of each as positive and negative con- trols, respectively. Next, a 1:10 dilution with normal saline of the Pfizer or Moderna vaccine was applied by prick technique. After 20 minutes, wheal sizes were measured and recorded. Whenever the result was negative, every 20 minutes a dosage of 0.05 mL of diluted vaccine was applied intradermally, starting with a 1:1000 dilution, then a 1:100 dilution, and finally a 1:10 dilution. After recording the final wheal size, pictures of the skin tests were taken, the patients were observed for an additional 30 minutes, and they were requested to submit pictures of their skin test at 4 to 6 hours after testing to evaluate late-phase reactions and at 24 hours after testing to evaluate delayed reactions. Afterward, the patients were evaluated by direct interviews for their reaction to subsequent vaccination. RESULTS The results are presented in Table 1 . There were 5 patients who had positive immediate skin reactions at doses ranging from 1:100 to 1:10 dilution of an mRNA vaccine. Of these patients, 1 had an anaphylactic reaction during skin testing of 1:100 dilution of the Moderna vaccine. These 5 patients also had positive late-phase reactions. There were 6 patients who had late-phase reactions without immediate reactions. Unfortunately, most patients did not comply with our request to submit pictures from delayed reaction. Patients with positive immediate reactions were recommended to receive the Janssen COVID-19 vaccine. Patients with negative immediate reactions (n = 25) were recommended to receive their choice of COVID-19 vac- cine. None of the patients with negative skin test result to an mRNA vaccine who were subsequently vaccinated to COVID-19 (n = 19, con- firmed through records in the Tennessee Immunization Information System) have had any allergic reaction to vaccination. After our risk assessment, 66% of the patients went on to receive full COVID-19 immunization.
By admin October 5, 2021
Take a Look: Facts and fiction behind popular allergy myths. AND: How you can protect yourself— all year long. We are about to embark upon the fall allergy season in full swing. It is important to know the dos and don’ts regarding allergies and what is actually accurate information surrounding them. After reading an article entitled “8 common myths about allergies,” written by Alistair Gardiner, we wanted to share useful information to help you prepare for not only fall allergy season, but all year long as well. ALL ABOUT POLLEN A lot of people dread to see flowers bloom in the spring, but according to research, the trees in that season, grasses in the summer, weeds in the fall, and mold spores, which can occur anytime, but primarily in the fall and winter, are the predominant culprits of allergy producing symptoms. This can produce allergic rhinitis, known to many as hay fever, which consists of sneezing, nasal drainage, chronic sinusitis, itchy, watery eyes, as well as asthma with cough and wheezing. During the allergy seasons individuals with allergy syndrome can feel more tired and irritable. This is because these particular pollens are airborne and are more likely to be inhaled through the nose and cause these symptoms rather than flower pollens, which appear to be larger and have a sticker texture allowing them to adhere to insects and not be as prevalent in the air. The pollens of trees, grasses, weeds, and mold spores cause many symptoms that we see daily in our clinics. We recommend allergy immunotherapy, also known as allergy injections, for sick patients with multiple symptoms which test positive for these allergens either by skin or blood test. A new treatment that has been introduced and effective in helping allergy suffers are immunological modifiers known as biologicals. PROGRESSION OF ALLERGY Another misconception is that if one never developed allergies as a child, one won’t every have problems with them in the future. According to Dr. Neeta Ogden of the ACAAI, age is not a factor for when allergies can occur. “In fact, more than half of adults with food allergies tend to develop them during adulthood” (Gardiner, 2021). More and more adults in their early adulthood (20s and 30s) are beginning to develop allergy syndrome, according to an allergist, Edward David, III, MD (Gardiner, 2021). This is a very common finding in our practice, and many are indeed shocked to not only develop environmental and food allergies at this later age, but sometimes life-threatening ones as well. Next, we look at the question, do allergies last forever? Many think they never go away. For some, that may be the case. Some have symptoms that come and go over times, and some do eventually develop an immunity to them as they age or complete their treatment plan. Typically symptoms of allergy change from acute, to subacute, to chronic with fatigue their primary complaint. Where there are environmental allergies like ragweed pollen in the fall, there are almost always food allergies because of the cross reactions between the two. So, the ragweed pollen allergen cross react with gourd plants and while eating those and exposure in weeds can increase symptoms. Avoiding these reactive foods helps decrease allergy or other symptoms that they may cause, and patients may eventually be able to tolerate them with more ease. Mayo Clinic states that about 60-80% of children with milk and/or egg allergies may be able to eat these foods without problems by the time they reach sixteen years of age (Gardiner, 2021). However, there are occasions where this is not possible despite treatment and/or avoidance. It appears that certain tree nuts and shellfish may pose a different stance, and these may never be able to be consumed without problems. PET ALLERGIES Next, we will discuss one of the most sensitive topics in allergy, and that is pets. These beloved creatures can cause an array of problems for their owners if they are allergic to them. What is one specifically allergic to regarding pets? The most common misconception is the fur itself. Instead, it has nothing to do with the fur at all. It is the dander, which contains all sorts of allergens, such as saliva, skin flakes, urine, and a multitude of other pollens they pick up when they are outside (Gardiner, 2021). Also, many think there are hypoallergenic dogs or cats, but according to the AAAI, that is not true (Gardiner, 2021). Certain pets may cause more allergy symptoms in certain people than others, but this is not related to its fur or certain breeds specifically. If one would still like their furry friends around, some things to do are to groom them regularly and try to keep them out of one’s bedding to decrease exposure. FOOD ALLERGY The next topic at hand is finding the difference between food allergies and food intolerances. Are they the same? The answer is no. Food allergies illicit an “adverse immune response to certain proteins, which lead to dermatologic, respiratory, gastrointestinal, cardiovascular, and/or neurologic symptoms” (Gardiner, 2021). As mentioned earlier, some allergies can trigger a near fatal experience, also known as anaphylaxis, especially certain foods for certain individuals. Food intolerances do NOT provoke an immune response but involve reaction due to toxicity or lack of some enzymes to process foods like lactase (associated with lactose intolerance). To manage immunological reactions of food we recommend cooking or fermenting most foods since it tends to denature most proteins, making reactive foods more tolerable. In addition to avoidance of reactive foods, adding probiotics from fermented food, and adhering to a paleo diet may help to decrease symptoms and strengthen the immune system. This is an approach also used in our clinics with success. Last, but not least, let’s discuss peanuts. Many think this food causes the most severe reactions of all foods. It does for some, but not for others. This is all contingent on one’s immune system as to how it responds. “According to Food Allergy Research and Education, there are actually eight foods identified as causing the most serous reactions for people in the U.S.” (Gardiner, 2021). They are crustacean shellfish, eggs, peanuts, milk, wheat, tree nuts, soy, and fish (Gardiner, 2021). It is important to understand myths regarding allergies because it can help one to know how to better protect oneself against symptomatology and/or potential life-threatening experiences.
By admin December 28, 2020
CDC's ACIP Expands on Precautions and Contraindications for Pfizer Vaccine New Updated Information as of January 6, 2021. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html What to know: “Severe allergic reaction (e.g., anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 vaccine is a contraindication to vaccination listed in the prescribing information. Anaphylactic reactions in persons outside of clinical trials have been reported. While these reports are further investigated, CDC considers a history of severe allergic reaction (e.g., anaphylaxis) to any other vaccine or injectable therapy (e.g., intramuscular, intravenous, or subcutaneous) as a precaution but not a contraindication to vaccination. In persons who report a history of anaphylaxis to another vaccine (i.e., any other vaccine besides the Pfizer-BioNTech COVID-19 vaccine) or injectable therapy, a risk assessment should be conducted to determine type of reaction and certainty of information. For example, whether the medication was administered by injection or another route or whether the reaction constituted a severe allergic reaction (e.g., required use of epinephrine [EpiPen®, etc.], resulted in hospitalization). These persons may still receive vaccination, but they should be counseled about the unknown risks of developing a severe allergic reaction and balance these risks against the benefits of vaccination. A history of mild allergic reaction to a vaccine or injectable therapy, such as urticaria alone without signs or symptoms of anaphylaxis, is not a contraindication or precaution to Pfizer-BioNTech COVID-19 vaccination. In addition, allergic reactions (including severe allergic reactions) not related to vaccines or injectable therapies (e.g., food, pet, venom, environmental, or latex allergies; oral medications [including the oral equivalents of injectable medications]) are not a contraindication or precaution to vaccination with Pfizer-BioNTech COVID-19 vaccine.” Additional discussion about clinical considerations for use of the vaccine can be found here . Allergists need to know that the CDC/ACIP/FDA and NIAID are aware of the reactions that have occurred and are actively working, along with leadership of the AAAAI, to determine the cause for these reactions, and developing protocols to help you deal with them. Added Precautions The CDC has also issued guidelines on precautions and management of anaphylaxis to sites that administer the vaccines. Recommendations are to avoid any other vaccinations for 14 days before or after the SARS-CoV-2 vaccine, but if you have had another vaccine within that 14 day window, don’t wait to get this vaccine. Recommendations are to defer vaccination for 90 days after receiving convalescent plasma or monoclonal antibody treatment for COVID-19. About the Moderna Vaccine: This vaccine has been granted an EUA and approval from the CDC/ACIP . Results from the clinical trials are very similar in efficacy and safety compared to the Pfizer vaccine. The FDA Briefing Document can be found here . This document presents both interim analysis using a data cutoff of November 7, with a median follow-up of 7 weeks post-dose one, and the final scheduled analysis from a data cutoff of November 21, with a median follow-up >2 months post-dose two. This summary covers the final scheduled analysis. Safety: The most common adverse reactions: injection site pain (91.6%), fatigue (68.5%), muscle pain (59.6%), joint pain (44.8%), chills (43.4%), fever (14.8%). Most of these were mild to moderate, began on day 1-2 and lasted 2 days. A small number of participants reported systemic reactions longer than 7 days, but there was no difference between vaccinated and placebo groups. Lymphadenopathy (axillary) was reported in 21.4% of vaccine recipients <65 years of age, and 12.4% in those >65 years of age, compared to 7.5% and 5.8% in placebo in those age groups respectively. Severe adverse reactions occurred in 0.2% to 9.7% of participants, and were more frequent after the second dose and less common in those 65 years of age and older. Hypersensitivity adverse events were slightly greater in the vaccine group (1.5%) compared to the placebo group (1.1%). There were no anaphylactic or severe hypersensitivity reactions. This vaccine also contains PEG in the lipid capsule. Serious adverse events were low (1.0%) without meaningful imbalances between study arms. Other than the differences in the age groups and reactogenic reactions, there were no safety differences with respect to race, ethnicity, gender or pre-existing conditions. Efficiency: Vaccine efficacy was 94.1% (95% CI 89.3%, 96.8%) with 11 cases of COVID-19 in the vaccine group and 185 cases in the placebo group. Unlike the interim data, the vaccine efficacy when stratified by age group was 95.6% (95% CI 90.6%, 97.9%) for participants 18 to <65 years of age and 86.4% (95% CI 61.4%, 95.5%) for participants 65 years of age or older. Other than the age group difference, there were no vaccine efficacy differences based on race, ethnicity, gender or medical comorbidities associated with high risk for severe COVID-19. Vaccine efficacy against severe COVID-19: 30 cases in the placebo group, 0 in the vaccine group. Vaccine efficacy after the first dose was 80.2% (95% CI, 55.2%, 92.5%) in the 2,000+ patients who only received one dose, but these patients were only followed for 28 days. *Efficacy against asymptomatic infection: preliminary data only, NP swabs were collected pre-dose one and pre-dose two. Number of positive swabs pre-dose two in negative baseline participants was 14 in the vaccine group and 38 in the placebo group, suggesting that some asymptomatic infections may be prevented with just the first dose.